Online edition:ISSN 2758-089X

Reactive oxygen metabolites as a biomarker of congenital heart disease in children

Brain natriuretic peptide (BNP), as a hematological biomarker, has been widely used in congenital heart disease (CHD). However, its sensitivity and specificity vary depending on age and pathological condition. In the present study, we assessed whether reactive oxygen metabolites (ROMs) and biological antioxidant potential (BAP), as oxidative stress indicators, could be new biomarkers in CHD. Forty-two patients diagnosed with CHD were enrolled in this study. The levels of ROMs, BAP, BNP, cardiac muscle creatinine kinase, and heart-type fatty acid-binding protein were measured using the findings of echocardiography. The ROM and BNP levels were significantly higher than the standard reference levels. The estimated Qp/Qs correlated mildly with BNP and ROM levels. The medication caused a significant decrease in BNP and ROM levels. The optimal decision, Qp/Qs greater than 1.5, estimated from receiver operator characteristic (ROC) curves was 371 U.CARR (58% sensitivity, 90% specificity) for ROMs, and that for BNP was 28.4 pg/ml (97% sensitivity 45% specificity). Direct comparison of ROMs and BNP did not show significantly different area under the curve values. ROM levels can be a new biomarker for oxidative stress evaluation in children with CHD at almost the same sensitivity as the previous biomarkers, and an effective indicator when combined with other biomarkers and indicators.

Ohno N, et al